Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 18, 2015
- Accepted in final form July 15, 2015
- First Published September 3, 2015.
Author Disclosures
- Luis Querol, MD, PhD,
- Ricard Rojas-García, MD, PhD,
- Jordi Diaz-Manera, MD, PhD,
- Joseba Barcena, MD,
- Julio Pardo, MD,
- Angel Ortega-Moreno, MD,
- Maria Jose Sedano, MD,
- Laia Seró-Ballesteros, MD,
- Alejandra Carvajal, MD,
- Nicolau Ortiz, MD, PhD,
- Eduard Gallardo, PhD and
- Isabel Illa, MD, PhD
- Luis Querol, MD, PhD,
NONE
NONE
(1) Bayer-Schering, travel grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Fondo de Investigaciones Sanitarias, Subprograma Juan Rodes, FIS JR13/00014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ricard Rojas-García, MD, PhD,
Serving on a scientific Advisory Board, Familial Amyloid Neuropathy, from Commercial entity, Pfizer.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jordi Diaz-Manera, MD, PhD,
NONE
NONE
Genzyme, speaker honoraria and travel grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joseba Barcena, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julio Pardo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angel Ortega-Moreno, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Jose Sedano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laia Seró-Ballesteros, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alejandra Carvajal, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolau Ortiz, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eduard Gallardo, PhD and
NONE
NONE
NONE
NONE
(1)TITLE: Blood-Based Assay for Dysferlinopathies INVENTORS (By order of signature): RH Brown, MF Ho, I Illa, E Gallardo N?: 7,172,858 PRIORITY COUNTRY: United States PRIORITY DATE: February 6th, 2007 ENTITY: Massachusetts General Hospital, Boston/ Hospital de Sant Pau, Barcelona XTENDED TO COUNTRIES: CANADA, JAPAN COMPANIES EXPLOITING IT: Athena Diagnostics, Worcester, USA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Isabel Illa, MD, PhD
NONE
NONE
Genzyme. Travel grant.
Neurologia, advisory board.
Dysferlin detection in monocytes. Athena Labs.
NONE
NONE
Grifols (commercial entity).
NONE
NONE
NONE
NONE
(1) FIS (Fondo de Investigaciones Sanitarias), ISCIII, Ministry of Healthe (Spain), 13/00937, 3 years.
NONE
(1) Fundacion Gemio
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuromuscular Diseases Unit (L.Q., R.R.-G., J.D.-M., E.G., I.I.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro para la Investigación Biomédica en Red en Enfermedades Raras (L.Q., R.R.-G., J.D.-M., E.G., I.I.), CIBERER, Madrid, Spain; Neurology Department (J.B.), Hospital Universitario de Cruces, Universidad del País Vasco, Spain; Department of Neurology (J.P.), Hospital Clínico de Santiago, Santiago de Compostela, Spain; Department of Neurology (A.O.-M., A.C.), Hospital Virgen de las Nieves, Granada, Spain; Department of Neurology (M.J.S.), University Hospital “Marqués de Valdecilla” (IFIMAV) and University of Cantabria, Santander, Spain; Department of Neurology (L.S.-B.), Hospital Univeristari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain; and Department of Neurology (UHN) (N.O.), Hospital Universitari Sant Joan, Universitat Rovira i Virgili, Reus, Spain.
- Correspondence to Prof. Illa: iilla{at}santpau.cat
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIgLuis Querol, Gisela Nogales-Gadea, Ricardo Rojas-Garcia et al.Neurology, February 12, 2014 -
Article
Anti-neurofascin antibody in patients with combined central and peripheral demyelinationNobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa et al.Neurology, July 24, 2013 -
Views & Reviews
Ultrastructural mechanisms of macrophage-induced demyelination in CIDPHaruki Koike, Ryoji Nishi, Shohei Ikeda et al.Neurology, November 14, 2018 -
Article
Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathiesElisabeth Burnor, Li Yang, Hao Zhou et al.Neurology, November 29, 2017